154229-18-2

• 常用中文名：乙酸阿比特龙酯
• 常用英文名：Abiraterone Acetate
• CAS号：154229-18-2
• 分子式：C₂₆H₃₃NO₂
• 分子量：391.546
• 相关类别： 有机原料 羧酸类化合物及衍生物 羧酸酯及其衍生物
• 发布时间：2018-02-08 08:00:00
• 更新时间：2026-07-02 01:45:26
• Abiraterone acetate是口服,有效,选择性和不可逆的 CYP17 抑制剂。

名称

• 中文名: 乙酸阿比特龙酯
• 英文名: abiraterone acetate
• 中文别名: 阿比特龙杂质04; (3BETA)-17-(3-吡啶基)-雄甾-5,16-二烯-3-乙酸酯; 乙酸阿比特龙; 醋酸阿比特龙(154-2); 阿比特龙乙酸盐; 乙酸阿比特龙酯、醋酸阿比特龙酯; 阿比特隆醋酸酯; 阿比特龙醋酸酯/乙酸阿比特龙酯; 乙酸[(3S,8R,9S,10R,13S,14S)-10,13-二甲基-17-(3-吡啶基)-2,3,4,7,8,9,10,11,12,13,14,15-十二氢-1H-环戊并[A]菲-3-基]酯; Abiraterone Acetate 5mg试剂; (3Β)-17-(3-吡啶基)雄甾-5,16-二烯-3-乙酸酯; 抑制剂Abiraterone acetate; CYP17抑制剂; 2H7]-醋酸阿比特龙; 乙酸阿比特龙酯 醋酸阿比特龙; 出售154229-,乙酸阿比特龙酯154-2; 阿比特龙醋酸盐; (3S,8R,9S,10R,13S,14S)-10,13-二甲基-17-(吡啶-3-基)-2,3,4,7,8,9,10,11,12,13,14,15-十二氢-1H-环戊烷并[A]菲-3-基 乙酸酯; Abiraterone Acetate :乙酸阿比特龙酯,阿比特龙醋酸酯; 醋酸阿比特龙酯; CB7630乙酸阿比特龙酯; 阿比特龙乙酸酯; 阿比特龙-3-位异构体杂质; Abiraterone Acetate (CB7630) 乙酸阿比特龙酯,阿比特龙醋酸酯,S2246; 醋酸阿比特龙杂质(6个); 醋酸阿比特龙ABIRATERONE ACETATE; 醋酸阿比特龙; 阿比特龙醋酸酯; 乙酸阿比特龙酯 ABIRATERONE ACETATE; ALFA-阿比特龙; Abiraterone Acetate (CB7630) 乙酸阿比特龙酯,阿比特龙醋酸酯，S2246; 乙酸阿比特龙酯,10 MM DMSO 溶液
• 英文别名: 17-(3-pyridyl)-5,16-androstadien-3beta-acetate; [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate; Abiraterone acetate (USFDA); 2-((3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodec; Abiraterone Impurity 81; (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate; Abiteron Acetate; Abiraterone Acotate; (3aS,3bR,7S,9,9bS,11aS)-9a,11a-dimethyl-1-(pyridin-3-yl)-3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-yl acetate; (3β)-17-(3-pyridinyl) androsta-5,16-dien-3-yl acetate; (3β)-17-(3-pyridyl)- androsta-5,16-dien-3-ol-acetate; (3)-17-(3-Pyridinyl)androsta-5,16-dien-3-ol Acetate (Ester); 8-Dihydroxyquinaldic acid; Abiraterone Acetate, 10 mM in DMSO; Abiraterone acetate - Bio-X; Abiraterone Acetate; 17-(3-pyridyl)-5,16-androstadien-3beta-acetatee; (3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-yl acetate; (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate; ABITATERONE ACETATE; Abiraterone Acetate impurity; (3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(3-pyridyl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl Acetate; Abiraterone Acetate D4Q: What is Abiraterone Acetate D4 Q: What is the CAS Number of Abiraterone Acetate D4 Q: What is the storage condition of Abiraterone Acetate D4 Q: What e the applications of Abiraterone Acetate D4; (3beta)-17-(3-pyridinyl)-Androsta-5,16-dien-3-ol acetate (ester); Abiraterone acetate ISO 9001：2015 REACH; 3-i-abiraterone Acetate stereoisomer; Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3β); Zytiga; Abiraterone Acetate >; 3beta-17-(3-Pyridyl)androsta-5,16-dien-3-ol Acetate; Abiraterone Acetate (Zytiga; ABIRATERONE ACTATE; formerly CB-7598; 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene; Abiraterone acetate - CB 7630 | JNJ; Abiraterone WS; Abiraterone acetate; Abiraterone acetate, >=; Androsta-5,16-dien-3-ol,17-(3-pyridinyl)-, acetate (ester), (3b); Androsta-5,16-dien-3-ol,17-(3-pyridinyl); ZYTIGA; Abiraterone acetate ester; Abiretorone; 2-((3S,8R,9S,10R,13S,14S)-10,13-diMethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)acetate; 17-(Pyridin-3-yl)androsta-5,16-dien-3β-yl acetate; Abirteroneacetate; Abiraterone acetate(CB7630); Abiraterone (acetate)

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 506.7±50.0 °C at 760 mmHg
• 熔点: 127-130°C
• 分子式: C₂₆H₃₃NO₂
• 分子量: 391.546
• 闪点: 260.2±30.1 °C
• 精确质量: 391.251129
• PSA: 39.19000
• LogP: 6.55
• 外观性状: 固体;White to Light yellow to Light orange powder to crystal
• 蒸汽压: 0.0±1.3 mmHg at 25°C
• 折射率: 1.584
• 储存条件: -20°C Freezer

生物活性

• 描述: Abiraterone acetate是口服,有效,选择性和不可逆的 CYP17 抑制剂。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 细胞色素P450
  研究领域 >> 癌症
• 靶点:

  CYP17[1]

• 体外研究: 阿比特龙(Abi)乙酸酯是抗癌剂阿比特龙的酯前药,对于17,20-裂解酶和17α-羟化酶显示IC 50值为15 nM和2.5 nM(CYP17是具有17α-羟化酶和17的双功能酶, 20-裂解酶活性)。阿比特龙抑制人17,20-裂解酶和17α-羟化酶,IC50分别为27和30 nM [1]。用阿齐拉酮≥5μM剂量显着抑制AR阳性前列腺癌细胞系LNCaP和VCaP的增殖[2]。阿比特龙抑制重组人3βHSD1和3βHSD2活性,竞争性Ki值为2.1和8.8μM。 10μM阿比特龙足以完全阻断两种细胞系中5α-二酮和DHT的合成。阿比特龙的治疗显着抑制稳健生长子集中的CRPC进展,有效地使治疗4周内肿瘤生长达到上限(P <0.00001) [3]。
• 体内研究: 阿比特龙(Abi)乙酸盐可延长去势抵抗性前列腺癌(CRPC)的存活率。 LNCaP中阿比特龙抑制[3H] -脱氢表雄酮(DHEA)消耗和Δ4-雄烯二酮(AD)积累,IC50 <1μM。先前显示0.5mmol/kg/d阿比特龙治疗剂量产生约0.5至1μM的血清浓度。对照组的异种移植肿瘤生长变化很大,一些肿瘤生长缓慢,只有一部分肿瘤表现出强劲的生长[3]。
• 细胞实验: 将LNCaP和VCaP细胞接种在96孔板中，并在补充CSS的无酚红或FBS补充的培养基中生长7天。在接种后24和96小时，用阿比特龙（5μM和10μM）处理细胞，并通过添加CellTiter Glo并测量发光在第7天测定细胞活力[2]。
• 动物实验: 小鼠[3]通过手术切除睾丸切除6至8周龄的雄性NOD / SCID小鼠，并植入5mg 90天持续释放DHEA小丸以模拟具有人肾上腺生理学的CRPC。两天后，用Matrigel皮下注射7×106个LAPC4细胞。肿瘤尺寸每周测量2至3次，体积计算为长×宽×高×0.52。一旦肿瘤达到300mm 3，将小鼠随机分配到载体或阿比特龙治疗组。阿比特龙组小鼠用5 mL / kg腹腔注射0.5 mmol / kg / d（0.1 mL 5％苄醇和95％红花油溶液）和对照小鼠仅用载体治疗，每日一次，每周5天以上持续4周（每次治疗n = 8只小鼠）。基于混合效应模型，通过ANOVA评估阿比特龙和媒介物治疗组之间的统计学显着性。
• 参考文献:

  [1]. Stein MN, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387-400.

  [2]. Richards J, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82.

  [3]. Li R, et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9.

  [4]. Lee GT, et al. Intracrine androgen biosynthesis in renal cell carcinoma. Br J Cancer. 2017 Mar 28;116(7):937-943.

安全

• 符号: GHS08
• 信号词: Danger
• 危害声明: H360-H372
• 警示性声明: P201-P260-P280-P308 + P313
• 靶器官: Endocrine system
• 危害码 (欧洲): Xi
• 危险品运输编码: NONH for all modes of transport
• RTECS号: BV7992100
• 海关编码: 2933399090

上下游产品

上游产品  10
115375-60-5 1692-25-7 108-24-7 154229-19-3
75-36-5 626-55-1 89359-48-8 853-23-6
89878-14-8 53-43-0
下游产品  1
154229-19-3

海关

海关编码	2933399090
中文概述	2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期
Summary	2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%